Please assess the completion status of the following clinical trial:

Trial Title: Different Noradrenaline Protocols in Post Spinal Hypotension in CS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA 2~* 38 +4 gestational age parturient~Exclusion Criteria:~* ASA 3-6~* Parturients with any kind of contraindication to spinal anesthesia~* Hypertensive parturients (basal systolic blood pressure above 140 mmHg)~* Parturients having basal systolic blood pressure below 100 mmHg~* Parturients having peripartum hemorrhage~* Parturients having body mass index above 40~* Parturients with a known allergic reaction to one of the study drugs~* Parturients not willing to be included into the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Noradrenaline 0.05/10 (Type: ACTIVE_COMPARATOR): Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus.
- Noradrenaline 0.075/5 (Type: ACTIVE_COMPARATOR): Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus.
- Noradrenaline 0.1/0 (Type: ACTIVE_COMPARATOR): Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute without bolus dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete